Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
12
% (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPNet Sales13,891¥ millionYear on year +12.0%Progress 51.4%
Operating profit1,950¥ millionYear on year +24.8%Progress 59.1%
Ordinary income2,125¥ millionYear on year +26.8%Progress 60.7%
Net income attributable to owners of the parent1,291¥ millionYear on year +16.7%Progress 58.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥173.63
Financial position at period-end
Total assets37,598¥ million
of which net assets 25,900 ¥ millionEquity ratio 63.9%vs. prior year-end -1.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+1,816,389
Investment-647,813
Financials-860,639
Net change+307,937
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥13,953,689 thousand
Segment revenueWater Healthcare Business ¥12,432 million (YoY +14.4%), Medical-related business ¥1,458 million (YoY -5.2%)
Segment profitWater Healthcare Business ¥1,825 million (YoY +25.4%), Medical-related business ¥124 million (YoY +16.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥27,000 million (YoY +11.8%)
Operating profit¥3,300 million (YoY +12.2%)
Ordinary income¥3,500 million (YoY +11.2%)
Net income¥2,200 million (YoY +8.3%)
Annual Dividend Forecast¥130 → ¥130（0.0%）
Factors Behind Changes in Business Performance
Sales of water ionizers and cartridges remained steady, while the bottled water business in Indonesia maintained strong growth. Although sales in the medical-related business declined, segment profit increased as costs were contained across the businesses.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not applicable / Excluded Number of companies 0 / Company name Not applicable
Breakdown of extraordinary income (loss)Extraordinary income Not applicable / Extraordinary loss Impairment loss on investment securities ¥1,000 thousand
Depreciation and amortization¥270,243 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors)
Issued Shares at Period-End8,656,780
Treasury Shares at Period-End1,211,084
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥13,891 million (YoY +12.0%) |
| Operating profit | ¥1,950 million (YoY +24.8%) |
| Ordinary income | ¥2,125 million (YoY +26.8%) |
| Profit attributable to owners of the parent | ¥1,291 million (YoY +16.7%) |
| Net income per share | ¥173.63 |
| Equity ratio | End of the current fiscal period 63.9 / End of previous period 65.8 |
| Total assets | ¥37,598 million |
| Net assets | ¥25,900 million |
| Cash flows from operating activities | ¥1,816,389 thousand |
| Cash flows from investing activities | ¥-647,813 thousand |
| Cash flows from financing activities | ¥-860,639 thousand |
| Cash and cash equivalents at end of period | ¥13,953,689 thousand |
| Full-year earnings forecast | Net Sales ¥27,000 million (YoY +11.8%) / Operating profit ¥3,300 million (YoY +12.2%) / Ordinary income ¥3,500 million (YoY +11.2%) / Net income ¥2,200 million (YoY +8.3%) |
| Annual Dividend Forecast | ¥130 → ¥130（0.0%） |
| Segment revenue | Water Healthcare Business ¥12,432 million (YoY +14.4%), Medical-related business ¥1,458 million (YoY -5.2%) |
| Segment profit | Water Healthcare Business ¥1,825 million (YoY +25.4%), Medical-related business ¥124 million (YoY +16.1%) |
| Depreciation and amortization | ¥270,243 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not applicable / Extraordinary loss Impairment loss on investment securities ¥1,000 thousand |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not applicable / Excluded Number of companies 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors) |
| Issued Shares at Period-End | 8,656,780 |
| Treasury Shares at Period-End | 1,211,084 |
| Factors Behind Changes in Business Performance | Sales of water ionizers and cartridges remained steady, while the bottled water business in Indonesia maintained strong growth. Although sales in the medical-related business declined, segment profit increased as costs were contained across the businesses. |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of water ionizers and cartridges remained steady, while the bottled water business in Indonesia maintained strong growth. In terms of profit, in addition to higher net sales, costs were contained in the medical-related business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.